Natco Pharma Board of Directors

Get the latest insights into the leadership at Natco Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. V C Nannapaneni Chairman & Managing Director
Mr. Rajeev Nannapaneni Vice Chairman & CEO
Mr. P S R K Prasad Director & Exe. VP (Corp. Engg. Services)
Dr. D Linga Rao Director & President (Tech. Affairs)
Mr. D Vijaya Bhaskar Independent Director
Mr. A D M Chavali Independent Director
Dr. Kantipudi Suma Independent Director
Mr. Nitin Jain Independent Director
Mr. Lakshminarayana Bolisetty Independent Director

Natco Pharma Share price

NATCOPHARM

00.0

0 (0.00%)
NSE
BSE
Last updated on 15 Oct, 2025 | 01:10 IST
BUYSELL
Today's High

00

Today's Low

00

52 Week Low

00

52 Week High

00

The current prices are delayed, login to your account for live prices

Natco Pharma FAQs

The board at Natco Pharma consists of experienced professionals, including Mr. V C Nannapaneni , Mr. Rajeev Nannapaneni , and others, overseeing the company’s strategic and corporate governance.

Directors at Natco Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. V C Nannapaneni is the current chairman at Natco Pharma.

Executive directors at Natco Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Natco Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Natco Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.